BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
Perhaps I am being pedantic but I would like a clearly stated study objective or hypothesis. The primary and secondary outcomes are well defined and reading the text I understand what the authors are trying to achieve but a few sentences that just say ' the objective of this study is to determine if using the TARB-Ex extraction tool in general practice and facilitating GP/practice nurse review of patients ..
I accept that pre/post intervention study has been chosen for pragmatic reasons but a more convincing methodology would have been a cluster RCT with usual care practices receiving education about FH and the need to intervene with cascade screening but not using TARB-Ex (for example).
It wasn't clear to me if the economic evaluation would include the cost of additional investigations and final treatment of individuals?
I think the study limitations of using a pre/post methodology should be added to the points already listed. It should also be acknowledged that patients in Australia can visit more than practice and duplication could occur. In addition a significant proportion of patients also move their residential address and practice in Australia every year, this may also affect the results and their interpretation.
I note this study probably does not need to be registered as it is not an RCT. The authors acknowledge pharmaceutical company funding. 2. I accept that pre/post intervention study has been chosen for pragmatic reasons but a more convincing methodology would have been a cluster RCT with usual care practices receiving education about FH and the need to intervene with cascade screening but not using TARB-Ex (for example).
REVIEWER
We have added the following to the list of limitations (Pg 3).
• Our pragmatic approach using existing clinical infrastructure enhances feasibility and sustainability but pre-post intervention comparison is acknowledged as potential limitation.
It wasn't clear to me if the economic evaluation would include the cost of additional investigations and final treatment of individuals?
This is now more explicitly stated in the Data Analysis section (Pg 13): Cost efficiency analysis: Costs collated from the start of the study to the endpoint at 12 months will be compared against historical costs sourced from tertiary centres for treating and managing FH cases. This will provide an indication of expenditures or savings from adopting the primary care based MoC. 4. I think the study limitations of using a pre/post methodology should be added to the points already listed. It should also be acknowledged that patients in Australia can visit more than practice and duplication could occur. In addition a significant proportion of patients also move their residential address and practice in Australia every year, this may also affect the results and their interpretation.
We have reworded the limitations to include the following (Pg 3):
• To the best of our knowledge this protocol is the first that focuses not just on early detection but also on the delivery of preventative care and management of FH in the primary care setting. It is trialled within the Australian context but builds on the consensus statements of the European Atherosclerosis Society1 and the International FH Foundation2 that FH care should ideally take place in the primary care setting.
• The GP and practice nurse (PN) team approach to phenotypic diagnosis and the cascade testing of FH relatives is likely to prove challenging initially from the GP/PN and patient perspective -length of follow-up to determine appropriate management of FH patients will be limited due to constraints of time and funding.
• There is potential for impact on the outcomes and interpretation as patients attending GP practices in Australia are not registered to a single practice -they may change residential address and be lost to follow-up or register at more than one practice with potential for duplication (or loss to follow-up if at a non-participating practice) however, this will be easily identified given the numbers of participants followed up.
• The potential for variability in compliance with medications (eg statins) and adherence to dietary and lifestyle advice across practices and between patients is acknowledged.
